The company’s ground-breaking preclinical data from its pipeline candidate, PBGENE-HBV, for chronic hepatitis B (HBV) treatment will be the core focus of this forthcoming presentation. The exceptional data pointing towards a breakthrough in HBV treatment will deliver a potentially better solution for millions suffering from the disease across the globe.
Chronic hepatitis B, a progressive condition, represents significant health problems worldwide, with about 257 million people living with the disease according to World Health Organization reports. In this context, Precision BioSciences’ PBGENE-HBV could prove to be a real game-changer, coming as gladdening news to millions of patients worldwide who could benefit significantly from such advanced treatment options.
Ernest Rady, the CEO of Precision BioSciences, expressed his confidence in the data to be presented. He stated, “Our data for PBGENE-HBV signifies a significant advancement in the field of gene-editing techniques aimed at developing more efficient, targeted treatment options. I am thrilled to see our work en
Comments